These data indicated that the anti-tumour effects of acetyl-bufalin were due to inhibition of CDK9/STAT3 in the PDX animal model and supported that acetyl-bufalin may display potential therapeutic effects in clinical trials. The gene discussed is CDK9; the disease is neoplasm.